Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTx-1302
- Development stage
- Unknown
- Lead developer
- Cingulate
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
CTx-1302 is a proprietary, extended-release oral tablet formulation of dextroamphetamine developed by Cingulate. It utilizes a breakthrough multi-core (triphasic) timed-release technology (OralogiK) designed to deliver rapid onset and sustained therapeutic levels throughout the entire active day for the treatment of attention-deficit/hyperactivity disorder (ADHD). The formulation aims to minimize afternoon "crash" and reduce the need for booster doses by providing immediate, delayed, and sustained drug release in one tablet. It is intended for use in children, adolescents, and adults with ADHD[1][4][9]. Dextroamphetamine acts as a central nervous system stimulant primarily through adrenergic receptor agonism.
- Brand names
- CTx-1302CTx1302CTx 1302
- Other names
- dextroamphetamine controlled releasedextroamphetamine sulphate (controlled release)
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)AR (Adrenergic receptors)
Beyond the preview
Go deeper on CTx-1302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTx-1302.